Introduction
============

COPD, according to the definition by the Global initiative for chronic Obstructive Lung Disease (GOLD), is a complex chronic airway disease characterized by persistent airflow limitation that is usually progressive.[@b1-copd-12-3245] This disease is now the third leading cause of death in the world.[@b2-copd-12-3245] The worldwide morbidity and mortality are expected to increase in the coming decades; as such, COPD poses a huge burden on the economy and society.[@b3-copd-12-3245] The strongest and most common risk factor for COPD is exposure to cigarette smoke (CS),[@b4-copd-12-3245] which leads to alveolar wall destruction with airspace enlargement (emphysema), one of the major pathologies of COPD.[@b1-copd-12-3245],[@b5-copd-12-3245] It is thought that CS-induced inflammation,[@b6-copd-12-3245] apoptosis,[@b7-copd-12-3245] and oxidative stress[@b8-copd-12-3245],[@b9-copd-12-3245] are the major drivers of emphysema.

Chen et al reported that interleukins (ILs)-1β play an important role in the inflammatory pathogenesis of emphysema in an animal model.[@b10-copd-12-3245] Apoptosis of alveolar wall cells has been observed in COPD, and has been related to disease progression.[@b7-copd-12-3245],[@b11-copd-12-3245],[@b12-copd-12-3245] The B-cell lymphoma-2 (Bcl-2) family of proteins is an essential factor that regulates apoptosis.[@b13-copd-12-3245],[@b14-copd-12-3245] Another major pathogenic factor contributing to emphysema/COPD is CS-associated oxidative stress, related to the formation of reactive oxygen species (ROS)/reactive nitrogen species.[@b15-copd-12-3245],[@b16-copd-12-3245] Endothelial cells produce nitric oxide synthase,[@b17-copd-12-3245] which has been correlated with alveolar repair in a rat model of pulmonary emphysema.[@b18-copd-12-3245]

Protein arginine methyltransferase 6 (PRMT6) is a nuclear enzyme that modifies histone tails.[@b19-copd-12-3245] It catalyzes the asymmetric dimethylation of histone H3 arginine 2 (H3R2me2a) specially. The trimethylation of H3 lysine 4 (H3K4me3) appears to counter-correlate with H3R2me2a in E-box-containing gene promoters.[@b20-copd-12-3245],[@b21-copd-12-3245] Interestingly, overexpression and knockdown analysis identify PRMT6 as a critical negative regulator of H3K4me3, which is related to global transcriptional activation in mammalian genomes.[@b22-copd-12-3245]--[@b24-copd-12-3245] In addition, the level of PRMT6 is associated with apoptosis in vivo.[@b25-copd-12-3245],[@b26-copd-12-3245] In our previous study,[@b27-copd-12-3245] human umbilical vein endothelial cells (HUVECs) transfected with PRMT6 expressing plasmid inhibited the cigarette smoke extract (CSE)-induced upregulation of Bcl-2-associated X protein (Bax) and cyclooxygenase-2 (COX-2). The inhibition of PRMT6 promoted the apoptosis and inflammation level in HUVECs induced by CSE. Meanwhile, CS-induced oxidative stress also has a close relationship with histone methylation, which could promote or depress gene activation.[@b28-copd-12-3245]

We hypothesized that the attenuation of PRMT6 may play a role in the pathogenesis of COPD and that upregulation of PRMT6 might possibly protect against CSE-induced emphysema in a mouse model. To the best of our knowledge, this study is the first investigation on the overexpression of PRMT6 with the aim of preventing CSE-induced emphysema in a mouse model by inhibiting inflammation, apoptosis, and oxidative stress at the mRNA and protein levels.

Materials and methods
=====================

Ethics statement
----------------

This study was approved by the Institutional Human and Animal Care Ethics Committee at the Second Xiangya Hospital of Central South University. Written informed consent was obtained from all human participants before their enrollment into the study.

Lung tissues of patients with COPD
----------------------------------

Pulmonary tissues were obtained from patients undergoing pneumonectomy at the Second Xiangya Hospital of Central South University between August 2012 and January 2013. Final diagnosis was benign lesions (such as lung abscesses and bullae), excluding cancer patients. Regarding smoking history and pulmonary function, the patients were divided into three groups: nonsmokers without COPD group (n=10), smokers without COPD group (n=10), and smokers with COPD group (stable stage, n=10). According to GOLD, the diagnosis of COPD was a post-bronchodilator forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) ≤0.7.[@b29-copd-12-3245]

Preparation of CSE
------------------

CSE was prepared following a modification of the method proposed by Zhang et al.[@b30-copd-12-3245] Briefly, five cigarettes (China Tobacco Hunan Industrial Co, Ltd, Hunan, China; tar: 12 mg, nicotine: 1.1 mg, carbon monoxide: 14 mg) were burned; the smoke was collected in a vessel containing phosphate-buffered saline (PBS; 10 mL). The pH of the solution was 7.2--7.4. CSE was prepared fresh before use.

Lentivirus plasmid and transduction
-----------------------------------

Lentivirus containing the PRMT6 gene was purchased from Thermo Fisher Scientific (Waltham, MA, USA). The lentivirus vectors were constructed by the company. The final concentration of the lentivirus was 1.0×10^9^ ifu/mL. The lentivirus was stored at −80°C and repetitive freeze--thaw occurred no more than three times.

Animal protocols
----------------

Six-week-old, male, specific pathogen-free, BALB/c mice (21--23 g each) were purchased from the Shanghai Animal Husbandry Advisory Services (China). The Second Xiangya Hospital Experimental Animal Center of Central South University was responsible for feeding. All animal care and experimental protocols were approved by the Animal Care and Use Committee of the Second Xiangya Hospital, Central South University, and were conducted in accordance with the committee's animal care and use guidelines. Thirty-two mice were randomly divided into four groups: the control group, CSE group, CSE + Lenti-NULL group, and CSE + Lenti-PRMT6 group, with eight mice in each group. The control group was injected intraperitoneally with 0.3 mL PBS at days 0, 11, and 22.[@b30-copd-12-3245] The other three groups were injected intraperitoneally with 0.3 mL CSE at days 0, 11, and 22. The control group and CSE group received intratracheal instillation of PBS at day 14. CSE + Lenti-NULL group and CSE + Lenti-PRMT6 group received an intratracheal instillation of 10^8^ ifu/mL (100 μL) Lenti-NULL and Lenti-PRMT6 correspondingly at day 14. All mice were sacrificed at day 28.

Lung tissues preparation
------------------------

The left lungs were inflated with 10% formalin at a constant pressure of 25 cm H~2~O and fixed for 24 hours. Paraffin-embedded sections were prepared using standard techniques.[@b31-copd-12-3245] Total protein and RNA were extracted from the right middle lobe and lower lobe separately as previously described.[@b30-copd-12-3245]

Morphometry
-----------

Lung sections were stained with hematoxylin and eosin (HE), and the morphology of lung tissues of mice was observed by light microscopy. The mean linear intercept (MLI) and destructive index (DI) were measured at a magnification of 100× as previously described.[@b32-copd-12-3245],[@b33-copd-12-3245]

Western blotting
----------------

In lung homogenates, the expression of PRMT6, H3R2me2a, and H3K4me3 in mouse and human samples, as well as Bcl-2, Bax, and endothelial nitric oxide synthase (eNOS) in mouse samples were detected by standard Western blotting techniques. Homogenate supernatants were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Beyotime Institute of Biotechnology, Shanghai, China), transferred onto polyvinylidene fluoride membranes, blocked for 1 hour, then washed, incubated with rabbit monoclonal antibodies against PRMT6, H3R2me2a, H3K4me3, Bcl-2, Bax, and eNOS (Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C. The next day, the membrane was washed and incubated for 2 hours at 37°C with HRP-labeled goat anti-rabbit secondary antibody (Santa Cruz Biotechnology Inc, Dallas, TX, USA), and then washed again. Labeled proteins were visualized by the electrochemiluminescence plus Western blotting detection system (Immobilon-P; EMD Millipore, Billerica, MA, USA). Band densities were quantified using Quantity One Analysis Software (Bio-Rad Laboratories Inc, Hercules, CA, USA).

Real-time quantitative polymerase chain reaction
------------------------------------------------

Total RNA was isolated from lung tissues of mice using Trizol reagent (Thermo Fisher Scientific) and then treated with DNase I (Thermo Fisher Scientific) according to the manufacturer's instructions. The primers used in this study were either synthesized according to previous protocols[@b27-copd-12-3245] or designed with Primer Premier 5.0 (Premier Biosoft international, Palo Alto, CA, USA). The sequences of the primers used in the present study were: actin-F: 5′-CATCCTGCGTCTGGACCTGG-3′;actin-R: 5′-TAATGTCACGCACGATTTCC-3′;IL-6-F: 5′-AGAACTCGAACGGGAACGCG-3′;IL-6-R: 5′-CGGCGACGGCAGACGGGC-3′;COX-2-F: 5′-TGCAGAATGTTGTTGTTTCTG-3′;COX-2-R: 5′-AATTAGAAACTTCAATCCGATTA-3′;Bcl-2-F: 5′-TGCAGAATGTTGTTGTTTCTG-3′;Bcl-2-R: 5′-AATTAGAAACTTCAATCCGATTA-3′;Bax-F: 5′-AGAACTCGAACGGGAACGCG-3′;Bax-R: 5′-CGGCGACGGCAGACGGGC-3′;eNOS-F: 5′-AGAACTCGAACGGGAACGCG-3′;eNOS-R: 5′-CGGCGACGGCAGACGGGC-3′.

Relative changes in transcript abundance were expressed as ^Δ^CT values (^Δ^CT = ^Δ^CT reference − ^Δ^CT target), where higher ^Δ^CT values indicate higher transcript abundance.

Statistical analysis
--------------------

A software package (SPSS 19.0; IBM Corporation, Armonk, NY, USA) was used to perform all statistical analyses. The data distribution was tested by the Shapiro--Wilk test. Continuous data were expressed as mean ± standard error of the mean. Differences were evaluated by one-way analysis of variance followed by the unpaired Student's *t*-test for multiple comparisons. Pearson's correlation was used to analyze the correlations between MLI and DI and the expression of PRMT6, H3R2me2a, and H3K4me3 in mice. A *p*-value \<0.05 was considered statistically significant.

Results
=======

Pulmonary function of patients
------------------------------

The pulmonary function test results of the patients are given in [Table 1](#t1-copd-12-3245){ref-type="table"}. Compared to the nonsmokers without COPD and smokers without COPD, FEV~1~ as a percentage of the normal predicted value (FEV~1~/pre\[%\]), FEV~1~/FVC (%), and peak expiratory flow (PEF) as a percentage of the normal predicted value (\[PEF\]/pre%) were lower in the smokers with COPD (*p*\<0.01).

Expression of PRMT6, H3R2me2a, and H3K4me3 in human lung tissues
----------------------------------------------------------------

As shown in [Figure 1](#f1-copd-12-3245){ref-type="fig"}, the protein abundance of PRMT6 was significantly decreased (*p*\<0.05) in lung tissues of patients with COPD compared with those subjects without COPD. Meanwhile, the protein abundance of H3R2me2 was significantly decreased and the protein abundance of H3K4me3 was significantly increased in the lung tissues of smokers with COPD compared with subjects without COPD, indicating a change in the expression of these proteins in COPD patients.

Histological examination of mice
--------------------------------

All HE stained lung tissue slices were observed at low magnification (100×). The CSE group showed CSE-induced alveolar airspace enlargement, lung parenchymal destruction, and inflammatory infiltration (*p*\<0.05, [Figure 2Ab](#f2-copd-12-3245){ref-type="fig"}). However, the CSE + Lenti-PRMT6 group showed significant improvements ([Figure 2Bd](#f2-copd-12-3245){ref-type="fig"}) in alveolar architecture in contrast to the CSE group and the CSE + Lenti-NULL group, but was still worse than the control group (*p*\<0.05, [Figure 2A](#f2-copd-12-3245){ref-type="fig"}).

Expression of PRMT6, H3R2me2a, and H3K4me3 in mice
--------------------------------------------------

As shown in [Figure 3](#f3-copd-12-3245){ref-type="fig"}, the protein abundance of PRMT6 was significantly decreased (*p*\<0.05) in the CSE group compared with the control group. The overexpression of PRMT6 was successful in mice with CSE-induced emphysema as the protein abundance of PRMT6 was significantly increased in the CSE + Lenti-PRMT6 group (*p*\<0.05) compared to that in the CSE group and the CSE + Lenti-NULL group. Moreover, the protein abundance of H3R2me2a was significantly decreased and H3K4me3 was significantly increased (*p*\<0.05) in the CSE group compared with levels in the control group. However, the protein abundance of H3R2me2a was significantly increased and H3K4me3 was significantly decreased in the CSE + Lenti-PRMT6 group with the overexpression of PRMT6 compared with mice not overexpressing PRMT6. As shown in [Figure 4](#f4-copd-12-3245){ref-type="fig"}, the expression of PRMT6 and H3R2me2a was negatively correlated with MLI and DI (*p*\<0.05). In addition, the expression of H3K4me3 was positively correlated with MLI and DI (*p*\<0.05).

Overexpression of PRMT6 inhibits inflammation in the lungs of mice with CSE-induced emphysema
---------------------------------------------------------------------------------------------

The CSE group showed increased expression of COX-2 and IL-6 in lung tissues compared with the control group and the CSE + Lenti-PRMT6 group (*p*\<0.05, [Figure 5](#f5-copd-12-3245){ref-type="fig"}). In addition, there were no significant differences between the CSE group and the CSE + Lenti-NULL group (*p*\>0.05, [Figure 5](#f5-copd-12-3245){ref-type="fig"}). The overexpression of PRMT6 attenuated the expression of inflammatory biomarkers.

Overexpression of PRMT6 inhibits apoptosis in the lungs of mice with CSE-induced emphysema
------------------------------------------------------------------------------------------

The Bcl-2 family proteins are essential factors that regulate apoptosis, and include antiapoptotic proteins and proapoptotic proteins. The CSE group showed decreased expression of Bcl-2 and increased expression of Bax in the lung compared with the control group and the CSE + Lenti-PRMT6 group (*p*\<0.05, [Figure 6](#f6-copd-12-3245){ref-type="fig"}). Lenti-NULL had no effect on the expression of Bcl-2 and Bax. The overexpression of PRMT6 inhibited apoptosis in the lungs of mice.

Overexpression of PRMT6 inhibits oxidative stress in the lungs of mice with CSE-induced emphysema
-------------------------------------------------------------------------------------------------

eNOS catalyzes the oxidation of NO, and is an important enzyme during oxidative stress. The CSE group showed decreased expression of eNOS in the lung tissues of mice compared with the control group and the CSE + Lenti-PRMT6 group (*p*\<0.05, [Figure 7](#f7-copd-12-3245){ref-type="fig"}). The expression of eNOS in the CSE + Lenti-PRMT6 group was lower than that in the control group (*p*\<0.05, [Figure 7](#f7-copd-12-3245){ref-type="fig"}). The overexpression of PRMT6 partly inhibited oxidative stress in the mouse lung.

Discussion
==========

This study demonstrated that the expression of PRMT6 was decreased in the lung tissues of mice with CSE-induced emphysema, which was confirmed in the lung tissues of COPD patients. The most remarkable finding of this study was that the overexpression of PRMT6 was able to partly reduce levels of biomarkers associated with inflammation, apoptosis, and oxidative stress in lung tissues of mice with CSE-induced emphysema. These results indicate that the overexpression of PRMT6 might inhibit the inflammatory response by reducing proinflammatory cytokine levels (such as COX-2, IL-6), attenuate apoptosis by affecting the expression of anti/proapoptotic factors (such as Bcl-2 and Bax), and downregulate the expression of eNOS in the oxidative stress pathway in the lung tissues of mice with CSE-induced emphysema.

The present mouse model of emphysema was established by an intraperitoneal injection of CSE every 11 days, that is, three times within 28 days. Airspace enlargement and alveolar destruction were evidenced by increases in MLI and DI in mice injected with CSE. The increases in MLI and DI were partly ameliorated by the intratracheal instillation of PRMT6 in mice with CSE-induced emphysema.

We found that PRMT6, a type of arginine methyltransferase, was downregulated in the lung tissues of COPD patients as well as in mice with emphysema. A previous study showed that CSE treatment decreased the protein abundance of PRMT6 in vitro,[@b19-copd-12-3245] but, the mechanism of the reduction was not described.[@b27-copd-12-3245] One possible mechanism might be related to activation of the ubiquitin--proteasome pathway, an ATP-dependent proteolytic pathway, in CSE-induced emphysema. Ottenheijm et al demonstrated that the reduced contractile protein content was attributed to increased activity of the ubiquitin--proteasome pathway in patients with COPD stage I/II.[@b34-copd-12-3245] Interestingly, the ubiquitin--proteasome system is also involved in the response to hypoxemia,[@b35-copd-12-3245] which is important in the pathogenesis of COPD. A growing body of evidence has shown that the ubiquitin--proteasome system plays a crucial role in the degradation of contractile proteins in patients with COPD.[@b36-copd-12-3245] Moreover, Kim et al demonstrated that apoptosis and cell cycle arrest induced by CS occurred partly through Akt degradation via the ubiquitin--proteasome system.[@b37-copd-12-3245] It is worth to further investigate the role of the ubiquitin--proteasome system in PRMT6 degradation, resulting in the attenuation of PRMT6 levels in mice with CSE-induced emphysema.

Chronic inflammation, apoptosis, and oxidative stress and the related networks are the most well-known and important mechanisms in cigarette smoking-induced emphysema. The present investigation undoubtedly demonstrates that the protective role of PRMT6 overexpression regarding inflammation, apoptosis, and oxidative stress was associated with alterations in pro-inflammatory cytokines (COX-2, IL-6), apoptosis biological markers (Bcl-2 family), and oxidative stress indicators (eNOS) in the mouse emphysematous lung. Moreover, the protective effects of PRMT6 overexpression on CSE-induced inflammation, apoptosis, and oxidative stress appeared to be mediated through H3R2me2a in emphysematous mice, because inhibition of PRMT6 in the CSE-induced emphysematous lung was associated with decreased expression of H3R2me2a and increased expression of H4K3me3 in the present study. In agreement with this, previous studies have indicated that PRMT6 catalyzes H3R2 dimethylation and controls global levels of H3R2me2a in vivo, which conversely prevents the di- and trimethylation of H3K4.[@b20-copd-12-3245],[@b21-copd-12-3245] Moreover, alterations to H3R2me2a correspond with CSE-induced inflammation and apoptosis.[@b27-copd-12-3245] All through, PRMT6 plays a potential oncogenic role in specific cancer tissue and tumor apoptosis.[@b38-copd-12-3245],[@b39-copd-12-3245] The molecular mechanism between PRMT6 and lung cancer is still unknown. Further investigation concerning PRMT6 and apoptosis in lung cancer should gain more concern. Furthermore, H3K4me3 has been found in the 5′ region of the transcribed genes and correlates with most of the genes expression.[@b22-copd-12-3245]--[@b24-copd-12-3245] Oxidative stress induced by CS leads to chromatin modifications (histone acetylation/deacetylation and histone methylation/demethylation), which result in gene activation (such as H3K4).[@b28-copd-12-3245] However, further investigation is necessary to investigate the detailed function of H3R2me2a and H3K4me3 in apoptosis, inflammation, and oxidative stress.

There are also some limitations in this study. We did not evaluate the level of ROS or antioxidant capacity in CSE-induced emphysema mice. The current results may not be sufficient to conclude that oxidative stress is implicated. Further studies are necessary to confirm this pathway.

In summary, the remarkable results of this study suggest that the overexpression of PRMT6 might partially protect against CSE-induced emphysema in mice through pathways relating to inflammation, apoptosis, and oxidative stress, mediated by H3R2me2a. This compelling finding is helpful for understanding the pathogenesis of COPD, and thus has important implications on the clinical treatment of COPD.
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![Expression of protein in the lung tissue of patients.\
**Notes:** Protein expression of PRMT6, H3R2me2a, and H3K4me3 (**A**). Lanes a1--3: nonsmokers without COPD; lanes b1--3: smokers without COPD; lanes c1--3: smokers with COPD. The quantitative analysis of blot density is also shown (**B**). \**p*\<0.05 in comparison with nonsmokers without COPD and smokers without COPD.\
**Abbreviation:** PRMT6, protein arginine methyltransferase 6.](copd-12-3245Fig1){#f1-copd-12-3245}

![Histological examination of mouse lungs.\
**Notes:** (**A**) Images depict the alveolar architecture (100× magnification) in the control group (a), CSE group (b), CSE + Lenti-NULL group (c), and CSE + Lenti-PRMT6 group (d). (**B**) Morphometric measurements of MLI (μm) and DI (%) were performed in each group. \**p*\<0.05 in comparison to the control group; ^\#^*p*\<0.05 in comparison to the CSE group; ^Δ^*p*\<0.05 in comparison to the CSE + Lenti-NULL group.\
**Abbreviations:** CSE, cigarette smoke extract; MLI, mean linear intercept; DI, destructive index; PRMT6, protein arginine methyltransferase 6.](copd-12-3245Fig2){#f2-copd-12-3245}

![Protein expression in mouse lung tissue.\
**Notes:** Expression of PRMT6, H3R2me2a, and H3K4me3 (**A**). Lanes C1 and 2: control group; lanes S1 and 2: CSE group; lanes N1 and 2: CSE + Lenti-NULL group; lanes P1 and 2: CSE + Lenti-PRMT6 group. The quantitative analysis of blot density is also shown (**B**). \**p*\<0.05 in comparison to the control group; ^\#^*p*\<0.05 in comparison to the CSE group; ^Δ^*p*\<0.05 in comparison to the CSE + Lenti-NULL group.\
**Abbreviations:** CSE, cigarette smoke extract; PRMT6, protein arginine methyltransferase 6.](copd-12-3245Fig3){#f3-copd-12-3245}

![Correlation between PRMT6, H3R2me2a, and H3K4me3 and MLI/DI.\
**Notes:** The expression of PRMT6 and H3R2me2a was negatively correlated with MLI (*p*\<0.05). In addition, the expression of H3K4me3 was positively correlated with MLI (*p*\<0.05) (**A**). There was the same correlation between the expression of these proteins and DI (**B**).\
**Abbreviations:** MLI, mean linear intercept; DI, destructive index; PRMT6, protein arginine methyltransferase 6.](copd-12-3245Fig4){#f4-copd-12-3245}

![Expression of IL-6 and COX-2 mRNA in mouse lung tissue.\
**Notes:** IL-6 and COX-2 mRNA levels were measured in mouse lung tissue. \**p*\<0.05 in comparison to the control group; ^\#^*p*\<0.05 in comparison to the CSE group; ^Δ^*p*\<0.05 in comparison to the CSE + Lenti-NULL group.\
**Abbreviations:** IL, interleukin; COX, cyclooxygenase; CSE, cigarette smoke extract; PRMT6, protein arginine methyltransferase 6.](copd-12-3245Fig5){#f5-copd-12-3245}

![Expression of Bcl-2 and Bax mRNA in mouse lung tissue.\
**Notes:** Protein expression of Bcl-2 and caspase-3 (**A**). Lanes C1 and 2: control group; lanes S1 and 2: CSE group; lanes N1 and 2: CSE + Lenti-NULL group; lanes P1 and 2: CSE + Lenti-PRMT6 group. The quantitative analysis of blot density is also shown (**B**). mRNA levels in mouse lung tissue (**C**). \**p*\<0.05 in comparison to the control group; ^\#^*p*\<0.05 in comparison to the CSE group; ^Δ^*p*\<0.05 in comparison to the CSE + Lenti-NULL group.\
**Abbreviations:** Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X protein; CSE, cigarette smoke extract; PRMT6, protein arginine methyltransferase 6.](copd-12-3245Fig6){#f6-copd-12-3245}

![Expression of eNOS in mouse lung tissue.\
**Notes:** Protein expression of eNOS (**A**). Lanes C1 and 2: control group; lanes S1 and 2: CSE group; lanes N1 and 2: CSE + Lenti-NULL group; lanes P1 and 2: CSE + Lenti-PRMT6 group. The quantitative analysis of blot density is also shown (**B**). mRNA levels in mouse lung tissue (**C**). \**p*\<0.05 in comparison to the control group; ^\#^*p*\<0.05 in comparison to the CSE group; ^Δ^*p*\<0.05 in comparison to the CSE + Lenti-NULL group.\
**Abbreviations:** eNOS, endothelial nitric oxide synthase; CSE, cigarette smoke extract; PRMT6, protein arginine methyltransferase 6.](copd-12-3245Fig7){#f7-copd-12-3245}

###### 

Patient demographics

                              Nonsmokers without COPD   Smokers without COPD   Smokers with COPD                                          *p*-value
  --------------------------- ------------------------- ---------------------- ---------------------------------------------------------- -----------
  Sex                                                                                                                                     
   Male                       7                         6                      9                                                          
   Female                     3                         4                      1                                                          
  Age (years)                 51.5±11.9                 52.4±12.5              59.8±13.7                                                  
  Smoking index (pack year)                             11.8±8.6               32.5±12.1[\*](#tfn2-copd-12-3245){ref-type="table-fn"}     \<0.01
  FEV~1~                      2.37±0.37                 2.45±0.32              1.91±0.40[\*](#tfn2-copd-12-3245){ref-type="table-fn"}     \<0.01
  FEV~1~/pre%                 94.28±8.63                93.95±8.36             67.18±11.96[\*](#tfn2-copd-12-3245){ref-type="table-fn"}   \<0.01
  FEV~1~/FVC%                 80.03±6.80                78.48±5.43             66.87±3.70[\*](#tfn2-copd-12-3245){ref-type="table-fn"}    \<0.01
  PEF/pre%                    92.30±22.50               89.59±26.77            58.11±17.60[\*](#tfn2-copd-12-3245){ref-type="table-fn"}   \<0.01

**Notes:** Data are presented as mean ± SEM.

*p*\<0.01 versus nonsmokers without COPD and smokers without COPD.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FEV~1~/pre%, FEV~1~ as a percentage of the normal predicted value; FVC, forced vital capacity; PEF, peak expiratory flow; PEF/pre%, PEF as a percentage of the normal predicted value; SEM, standard error of the mean.
